Citalopram: Nursing Drug Guide, QT Prolongation & NCLEX Review
Dose-dependent QTc prolongation, the 40 mg ceiling, and the 20 mg cap in older adults and hepatic impairment—plus serotonin syndrome when serotonergic drugs or MAOIs are missed on reconciliation.
Citalopram causes dose-dependent QTc prolongation; dosages above 40 mg once daily are not recommended. In patients older than 60 years, with hepatic impairment, or taking CYP2C19 inhibitors, the maximum is 20 mg once daily. Concomitant MAOIs (including linezolid or intravenous methylene blue within 14 days) or pimozide are contraindicated. Stacking with other serotonergic agents increases serotonin syndrome risk. Monitor for suicidal thoughts and behaviors, especially after initiation or dose changes. Discontinue gradually when stopping therapy.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm the ordered mg is within label limits for age and hepatic status, screen for new serotonergic or QT-prolonging drugs, and trend QTc and electrolytes when risk factors are present. Hold and clarify if dose exceeds 40 mg/day, if QTc is persistently >500 ms, or if serotonin syndrome or suicidality emerges.
Most common brand names
Citalopram is available as generic tablets and oral solution and as the brand Celexa. Always verify both drug name and tablet strength—look-alike SSRI names and 20 mg versus 40 mg strengths are common sources of inpatient errors.
Single-entity products include citalopram tablets (10 mg, 20 mg, 40 mg) and citalopram oral solution. Do not confuse escitalopram (active S-isomer) with racemic citalopram—they are not milligram-equivalent.
Why we give it — Indications
Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder (MDD) in adults. It is not approved for pediatric patients per prescribing information.
| Use | Detail |
|---|---|
| Major depressive disorder (adults) | First-line SSRI therapy per prescriber and local formulary; antidepressant benefit may take weeks—monitor suicidality and adverse effects during initiation and dose changes. |
| Off-label uses | Not specified in the reviewed prescribing information for additional labeled indications; use only per prescriber order and institutional policy. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The mechanism of citalopram is presumed to involve potentiation of central serotonergic activity through inhibition of neuronal serotonin (5-HT) reuptake. It is a selective SSRI with minimal effects on norepinephrine and dopamine reuptake per labeling. Cardiac electrophysiology studies show dose-dependent QTc prolongation, which drives the 40 mg maximum and enhanced monitoring in at-risk patients.
Dosing overview
Dosing is once daily with or without food. Increase at intervals of no less than one week. Do not exceed 40 mg once daily because of QT prolongation risk. Cap at 20 mg once daily in patients older than 60 years, with hepatic impairment, CYP2C19 poor metabolizers, or when taking CYP2C19 inhibitors such as omeprazole or cimetidine.
Missed dose: If a dose is missed, take the next dose at the regular time—do not double doses. Follow prescriber or pharmacy guidance for outpatient missed doses; document inpatient omissions per protocol.
Before you give it — Safety check
Pretreatment checks
- Confirm indication, allergies, and that patient is not taking MAOIs or pimozide; verify ≥14-day washout when switching antidepressants
- Verify dose ≤40 mg/day (≤20 mg/day if age >60, hepatic impairment, or CYP2C19 inhibitor); review QT-prolonging and serotonergic medications
- Screen for suicidal ideation, bipolar history, electrolyte/cardiac risk (K+, Mg2+, ECG baseline when indicated)
Contraindications
- Concomitant MAOIs or use within 14 days of stopping an MAOI (includes linezolid or IV methylene blue per labeling)
- Concomitant pimozide
- Known hypersensitivity to citalopram or formulation excipients (angioedema/anaphylaxis reported)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAOIs / linezolid / IV methylene blue | Contraindicated — serotonin syndrome risk | Hold citalopram; ensure 14-day washout before/after MAOI; never start concurrently |
| Serotonergic drugs (e.g., tramadol, fentanyl, triptans) | Increased serotonin syndrome risk | Medication reconciliation each shift; hold and escalate if hyperthermia, agitation, clonus |
| QT-prolonging drugs / electrolyte loss | Additive QTc prolongation; torsade de pointes risk | Baseline and trend ECG; correct K+/Mg2+; avoid combo when possible |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or oral solution once daily, with or without food.
- Give at the same time each day to support adherence and steady state (mean half-life ~35 hours)
- Use the prescribed strength (10 mg, 20 mg, 40 mg)—do not substitute escitalopram or another SSRI without prescriber order
- When tapering or discontinuing, reduce gradually when possible—abrupt stop increases discontinuation syndrome risk
Dosages above 40 mg once daily are not recommended because of dose-dependent QT prolongation. Patients older than 60 years, with hepatic impairment, or taking CYP2C19 inhibitors must not receive more than 20 mg once daily unless benefits clearly outweigh risks with ECG monitoring.
Expected therapeutic response
- Gradual improvement in depressive symptoms over weeks—not immediate
- Improved sleep, interest, or concentration may lag behind early GI or activation side effects
- Reassess continued need periodically per prescriber—maintenance trials support relapse prevention with ongoing therapy
Red flags — Stop and act
Escalate urgently when cardiac, serotonergic, or neuropsychiatric toxicity is suspected.
- Palpitations, syncope, dizziness suggesting arrhythmia—obtain ECG; discontinue if QTc persistently >500 ms
- Serotonin syndrome: agitation, hallucinations, tachycardia, labile BP, hyperthermia, tremor, rigidity, diarrhea
- New or worsening suicidal thoughts or behaviors, especially in young adults
- Seizure, coma, or altered mental status (including overdose)
- Severe hyponatremia signs: confusion, weakness, unsteadiness, seizures
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, dry mouth, diarrhea, dyspepsia | Common in MDD trials (e.g., nausea 21%, dry mouth 20% at ≥5% and greater than placebo) | Supportive care; assess hydration; document if persistent or severe |
| Somnolence, insomnia, anxiety, agitation | Common psychiatric/neurologic effects in trials | Monitor mood and sleep; screen for suicidality and serotonin syndrome if worsening |
| Dizziness, tremor | Common; dizziness led to discontinuation more often than placebo in trials | Fall precautions; orthostatic vitals; hold if syncope or arrhythmia symptoms |
| QTc prolongation / torsade de pointes | Serious; dose-dependent; postmarketing reports | Hold, obtain ECG, correct electrolytes, notify prescriber; discontinue if QTc persistently >500 ms |
| Serotonin syndrome | Potentially life-threatening; risk with serotonergic co-medications or MAOIs | Stop citalopram and serotonergic agents; supportive care; urgent escalation |
| Hyponatremia / SIADH | Serious; serum sodium <110 mmol/L reported | Check sodium if confusion, weakness, falls; hold and treat per protocol |
| Bleeding (GI, ecchymosis) | Increased risk with aspirin, NSAIDs, warfarin per labeling | Monitor for bruising, GI bleeding; educate on reporting melena or hematemesis |
| Sexual dysfunction | Common in trials (e.g., ejaculatory delay in males) | Nonjudgmental assessment; coordinate with prescriber if adherence affected |
On a small screen, swipe or scroll sideways to see the full table.
Frequency data above reflect CELEXA placebo-controlled MDD trial labeling unless noted as postmarketing.
Overdose, toxicity, and antidote
CELEXA overdosage has been reported with serotonin syndrome (higher risk with multiple proserotonergic drugs), cardiovascular toxicity (including QRS and QTc prolongation, wide-complex tachyarrhythmias, and torsade de pointes), delayed seizures, and altered mental status including coma. Hypertension is most commonly seen; hypotension may occur, including with alcohol co-ingestion.
Antidote
Not specified in the reviewed prescribing information — management is supportive. Consider activated charcoal if presentation is early. Prolonged cardiac monitoring is recommended because arrhythmia risk may be delayed.
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for overdose management recommendations.
Look-alike / sound-alike and error prevention
- Citalopram vs escitalopram — different active isomer and dosing; verify generic name on every administration
- Celexa vs Celebrex (celecoxib) — sound-alike brand names; confirm antidepressant vs NSAID
- 20 mg vs 40 mg tablets — double-check strength against age/hepatic/CYP2C19 limits before dispensing or administering
- SSRI cross-dispense — sertraline, fluoxetine, paroxetine are not interchangeable milligram-for-milligram
- MAOI washout — 14-day gap required when switching to or from MAOIs; document stop dates in MAR and reconciliation
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May be given with or without food per labeling. |
| Crush/split | Institutional protocols and product formulations may vary; verify scored tablet handling and enteral tube compatibility with pharmacy. |
| Onset | Antidepressant effect is not immediate; educate that benefit may take several weeks while monitoring for early adverse effects. |
| ECG timing | Obtain baseline ECG when cardiac risk or QT-prolonging co-medications are present; repeat when dose increases or symptoms suggest arrhythmia. |
| Commonly missed | Home SSRI duplicates, new tramadol or triptan orders, and 40 mg doses in patients >60 years. |
| Ask pharmacy when | Unclear dose for age/hepatic status, new QT-prolonging drug, or suspected serotonin syndrome. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Age >60 years | Higher drug exposure and maximum recommended dose 20 mg once daily; greater hyponatremia risk per labeling |
| Hepatic impairment / CYP2C19 poor metabolizers | Maximum 20 mg once daily; higher plasma levels increase QT prolongation risk |
| Cardiac disease / electrolyte imbalance | Avoid in congenital long QT, recent MI, uncompensated heart failure, bradycardia, hypokalemia or hypomagnesemia unless benefits outweigh risks with monitoring |
| Pregnancy | SSRIs including citalopram: epidemiologic studies have not established increased major birth defect risk, but PPHN and neonatal adaptation symptoms may occur with late-pregnancy exposure. Weigh untreated depression risks vs drug risks; pregnancy exposure registry available per labeling. |
| Lactation | LactMed: citalopram enters breast milk at low relative infant doses; minor infant effects (somnolence, fussiness, poor feeding) reported—monitor infants. If citalopram is required, breastfeeding is not automatically contraindicated; coordinate with prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mental status and suicidal ideation—especially first months and after dose changes
- ECG/QTc when cardiac risk, dose >20 mg in vulnerable patients, or new QT-prolonging drugs; discontinue if QTc persistently >500 ms
- Sodium (hyponatremia), especially older adults on diuretics; fall risk with dizziness
Document
- Dose, route, time, and tablet strength administered
- Suicide risk screening, serotonin syndrome assessment, and patient response/teaching provided
- ECG results, QTc values, electrolyte corrections, and prescriber/pharmacy notifications
Patient teaching
- Take exactly as prescribed; do not stop abruptly—contact clinician before stopping
- Report palpitations, fainting, fast irregular heartbeat, dizziness, fever, muscle rigidity, or confusion immediately
- Report worsening depression, suicidal thoughts, or unusual behavior changes—especially early in therapy
- Avoid starting MAOIs, St. John’s wort, or extra serotonergic drugs without medical advice
- Full antidepressant effect may take several weeks; continue unless prescriber directs otherwise
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Ordered dose >40 mg/day, or >20 mg/day when age >60, hepatic impairment, or CYP2C19 inhibitor without documented exception
- Patient on MAOI, linezolid, IV methylene blue, or pimozide; or within 14-day MAOI washout window
- QTc persistently >500 ms, new syncope/palpitations pending ECG, or uncorrected hypokalemia/hypomagnesemia
- Suspected serotonin syndrome, seizure, or severe hyponatremia symptoms
- New suicidal intent, mania, or angioedema/anaphylaxis
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Citalopram safety on shift centers on dose verification, interaction surveillance, and QT/serotonin vigilance—especially after new orders or dose increases.
1. Check-before-you-give protocol
- Right patient, drug, dose (≤40 mg; ≤20 mg if elderly/hepatic/CYP2C19 inhibitor), route, and time
- Review MAR + home meds for MAOIs, linezolid, serotonergic analgesics, and QT-prolonging agents at admission and after every new order
- Check latest ECG/electrolytes when ordered or clinically indicated
- Brief mood/suicide screen and fall risk if dizziness or sedation present
2. High-alert and safety badge
Not an ISMP high-alert medication — still requires QT and serotonin safety checksAlthough not classified as a high-alert drug in the same tier as IV anticoagulants or concentrated electrolytes, citalopram carries boxed warnings for suicidality and has FDA dose limits for QT prolongation—treat dose and interaction checks as mandatory high-risk nursing steps.
3. Clinical workflow: hold and question rules
- Hold and clarify any 40 mg order for a patient >60 years until prescriber documents risk-benefit with monitoring plan
- Stop and notify prescriber if serotonin syndrome criteria met—do not administer next dose
- Coordinate gradual taper with prescriber when discontinuing after prolonged use
4. Critical teach-back questions
- “What is your maximum daily dose and what symptoms should you report right away?” — patient states prescribed mg, knows not to exceed prescriber limit, and will report palpitations, confusion, fever, rigidity, or suicidal thoughts
- “What should you do before taking a new pain medicine or antibiotic?” — contact prescriber/pharmacy first because some drugs interact (serotonin syndrome or QT risk)
5. Care coordination
Pharmacist: Dose verification for age/hepatic status, interaction checks (CYP2C19 inhibitors, serotonergic agents), and ECG/electrolyte planning
Prescriber / mental health: Suicide risk management, taper plans, switching antidepressants with required MAOI washout, and alternative therapy if QT risk unacceptable
🧠 Quick mental checklist
- Is today’s dose ≤40 mg—and ≤20 mg if the patient is >60 or has hepatic/CYP2C19 concerns?
- Any new serotonergic or QT-prolonging drug in the last 24 hours?
- Latest QTc and potassium/magnesium when cardiac risk is present?
- Any suicidal statements, agitation, fever, or clonus suggesting serotonin toxicity?
- Is this citalopram—not escitalopram—and the correct tablet strength?
Citalopram NCLEX practice questions
Practice NCLEX-style clinical judgment practice for citalopram using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes around QT limits and serotonin safety.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Citalopram 40 mg PO daily scheduled — 0800 given today
- Tramadol 50 mg PO q6h PRN pain — 1 dose at 0730
- Omeprazole 20 mg PO daily — 0800
- PRN lorazepam available — not given
- Potassium 3.2 mmol/L (low)
- Magnesium 1.4 mg/dL (low-normal)
- Sodium 136 mmol/L
- ECG QTc: 468 ms (admission) → 492 ms (today 1000)
- BP 108/62 mmHg, HR 102/min, RR 18, SpO2 97% on room air, temp 37.1 °C
- Orthostatics: BP 106/60 lying → 98/58 standing; reports lightheadedness
- 72-year-old with MDD on medical unit; weight 58 kg
- 1005: New palpitations and intermittent dizziness; no syncope
- 1015: Son reports patient took extra “antidepressant pill” from home bottle before admission—strength unknown
- 1020: Nurse reviewing MAR and labs before 1200 dose
Answer key & rationale
Frequently asked questions
What is the maximum citalopram dose nurses should verify on the MAR?
For most adults, initial treatment is 20 mg once daily with a maximum of 40 mg once daily after at least one week. Dosages above 40 mg once daily are not recommended because of QT prolongation. Patients older than 60 years, with hepatic impairment, or taking CYP2C19 inhibitors (e.g., omeprazole, cimetidine) should not receive more than 20 mg once daily unless benefits clearly outweigh risks with monitoring.
When should a nurse hold citalopram and contact the prescriber or pharmacist?
Hold when the dose exceeds labeling limits for the patient’s age or hepatic status, when MAOIs, linezolid, IV methylene blue, or pimozide are present or within the 14-day MAOI washout, when QTc is persistently greater than 500 ms, when serotonin syndrome is suspected, or when new suicidal intent, mania, or severe hyponatremia symptoms appear.
Is there a specific antidote for citalopram overdose?
Not specified in the reviewed prescribing information. Overdose management is supportive, with consideration of activated charcoal if early presentation and prolonged cardiac monitoring for delayed arrhythmias. Contact local poison control or medical toxicology services per facility protocol.
Can patients breastfeed while taking citalopram?
LactMed reports citalopram is present in breast milk at low relative infant doses; minor infant effects such as somnolence or poor feeding have been reported. If citalopram is required, breastfeeding is not automatically contraindicated—monitor the infant and coordinate with the prescriber.
Why is citalopram confused with escitalopram on nursing units?
The names sound similar and both are SSRIs, but escitalopram is the active S-isomer with different dosing and exposure. Always verify the exact generic name and strength on the label and MAR before administration.
References
-
U.S. National Library of Medicine. CELEXA (citalopram) tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177
-
U.S. Food and Drug Administration. Celexa (citalopram) tablets — Prescribing information (label 2024).https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020822s055lbl.pdf
-
Drugs and Lactation Database (LactMed). Citalopram. Bethesda (MD): NICHD; updated 2025 Feb 15.https://www.ncbi.nlm.nih.gov/books/NBK501185/
-
U.S. Food and Drug Administration. FDA drug safety communication: revised recommendations for Celexa and related drugs.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-related-drugs-given-oral-doses
-
National Institute of Mental Health. Depression — patient and clinician overview.https://www.nimh.nih.gov/health/topics/depression
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.